60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Rhea-AI Summary
60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported that it has enrolled the minimum 24 hospitalized patients required to trigger an interim analysis in its double-blind, randomized, placebo-controlled Phase 2/3 trial of oral tafenoquine plus standard of care for severe babesiosis (NCT06207370). The data safety and monitoring board will analyze the primary endpoint of time to sustained clinical recovery and the key secondary endpoint of time to molecular clearance of Babesia parasites, with topline interim results expected by October 6, 2026.
Depending on statistical significance, the board may recommend early study halt, additional enrollment, or study closure. Enrollment will continue during this period. Following the interim analysis, 60 Degrees plans to request an FDA meeting to discuss the regulatory pathway for a potential supplemental NDA for tafenoquine in babesiosis. Tafenoquine (marketed as ARAKODA for malaria prophylaxis) is not currently approved for treating or preventing babesiosis, and no FDA-approved therapies exist for this disease.
Positive
- Minimum 24-patient enrollment threshold reached to trigger interim analysis in severe babesiosis trial
- Interim data readout for hospitalized babesiosis study expected by October 6, 2026
- Study design is double-blind, randomized, multisite, placebo-controlled across major U.S. medical centers
- If primary endpoint reaches statistical significance, DSMB may halt study early based on results
- Company plans to seek FDA meeting on supplemental NDA pathway for tafenoquine in babesiosis
Negative
- Tafenoquine is not FDA-approved for babesiosis, and there is no approved treatment or vaccine for the disease
Market Reaction – SXTP
Following this news, SXTP has gained 1.46%, reflecting a mild positive market reaction. Argus tracked a peak move of +15.8% during the session. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner has triggered 20 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $1.51. Trading volume is exceptionally heavy at 6.8x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 08 | University option agreement | Positive | -4.3% | Exclusive university option agreement advanced castanospermine development for multiple tick-borne diseases. |
| Jul 01 | Clinical trial update | Positive | -0.6% | DSMB found no safety concerns in six patients and recommended study continuation. |
| Jun 11 | Patent license agreement | Neutral | +0.0% | Exclusive patent license and FDA non-notification letter addressed botanical supplement development pathway. |
| May 26 | Clinical enrollment update | Positive | +1.4% | First seasonal patient enrolled ahead of schedule in randomized hospitalized babesiosis trial. |
| May 15 | First-quarter earnings | Negative | -4.8% | First-quarter results showed lower revenue, higher expenses, and a per-share net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history showed negative reactions to two positive developments, while a clinical enrollment update gained 1.35%.
Key Terms
interim analysis medical
data safety and monitoring board medical
supplemental NDA regulatory
G6PD deficiency medical
methemoglobinemia medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis
WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (NCT06207370). The outcome of the interim analysis will be disclosed no later than October 6, 2026. Enrollment will continue in the interim.
60 Degrees is the sponsor of a double-blind, randomized, multisite, placebo-controlled clinical trial entitled “Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis,” which evaluates the efficacy and safety of tafenoquine in treating severe babesiosis in humans. Patients are enrolled at multiple sites in the U.S., including Tufts Medical Center, Rhode Island Hospital, Yale University, Brigham and Women’s Hospital, and Westchester Medical Center.
The study’s data safety and monitoring board (DSMB) will conduct the interim analysis for the study. Time to sustained clinical recovery from babesiosis (primary endpoint) and time to molecular clearance of Babesia parasites (key secondary endpoint) will be analyzed. If statistical significance is reached for the primary endpoint, the study will be halted early. For either endpoint, the DSMB could recommend enrolling more patients or that the study should be closed if statistical significance is not achieved or is unlikely to be achieved with additional enrollment.
Following the interim analysis, the Company intends to seek a meeting with the U.S. Food and Drug Administration (FDA) to discuss data requirements for potential submission of a supplemental NDA.
No FDA-approved treatment or vaccine exists for babesiosis. Tafenoquine is not currently approved by the FDA for the treatment and prevention of babesiosis. Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA® (tafenoquine).
About ARAKODA® (tafenoquine)
Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel.
ARAKODA® (tafenoquine) Important Safety Information
ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older.
Contraindications
ARAKODA® should not be administered to:
- Glucose-6-phosphate dehydrogenase (“G6PD”) deficiency or unknown G6PD status;
- Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if
- G6PD status is unknown;
- Patients with a history of psychotic disorders or current psychotic symptoms; or
- Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®.
Warnings and Precautions
Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.
G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant’s G6PD status before breastfeeding begins.
Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.
Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible.
Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy.
Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration.
Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety.
Drug Interactions
Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters.
Use in Specific Populations
Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®.
To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The full prescribing information of ARAKODA® is located here.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or castanospermine in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Media Contact:
Kristen Landon
kristenlandon@60degreespharma.com
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
